They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...
The subgroup of patients with asthma using benralizumab with high BEC and high FeNO had the highest rates of super-responders (83.3%) and clinical remission (70.0%). Benralizumab is effective in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback